Amedee Renand1, Mohamed H Shamji2, Kristina M Harris3, Tielin Qin3, Erik Wambre1, Guy W Scadding4, Peter A Wurtzen5, Stephen J Till6, Alkis Togias7, Gerald T Nepom8, William W Kwok1, Stephen R Durham9. 1. Benaroya Research Institute at Virginia Mason, Seattle, Wash. 2. Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Section of Inflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London, United Kingdom; MRC and Asthma UK, Centre in Allergic Mechanisms of Asthma, London, United Kingdom. 3. Immune Tolerance Network, Bethesda, Md. 4. Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Section of Inflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London, United Kingdom. 5. Immunology, ALK-Abelló, Hørsholm, Denmark. 6. Asthma, Allergy and Lung Biology, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom; MRC and Asthma UK, Centre in Allergic Mechanisms of Asthma, London, United Kingdom. 7. National Institute of Allergy and Infectious Diseases, Bethesda, Md. 8. Benaroya Research Institute at Virginia Mason, Seattle, Wash; Immune Tolerance Network, Bethesda, Md. 9. Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Section of Inflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London, United Kingdom; MRC and Asthma UK, Centre in Allergic Mechanisms of Asthma, London, United Kingdom. Electronic address: s.durham@imperial.ac.uk.
Abstract
BACKGROUND: Three years of treatment with either sublingual or subcutaneous allergen immunotherapy has been shown to be effective and to induce long-term tolerance. The Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (GRASS) trial demonstrated that 2 years of treatment through either route was effective in suppressing the response to nasal allergen challenge, although it was insufficient for inhibition 1 year after discontinuation. OBJECTIVE: We sought to examine in the GRASS trial the time course of immunologic changes during 2 years of sublingual and subcutaneous immunotherapy and for 1 year after treatment discontinuation. METHODS: We performed multimodal immunomonitoring to assess allergen-specific CD4 T-cell properties in parallel with analysis of local mucosal cytokine responses induced by nasal allergen exposure and humoral immune responses that included IgE-dependent basophil activation and measurement of serum inhibitory activity for allergen-IgE binding to B cells (IgE-facilitated allergen binding). RESULTS: All 3 of these distinct arms of the immune response displayed significant and coordinate alterations during 2 years of allergen desensitization, followed by reversal at 3 years, reflecting a lack of a durable immunologic effect. Although frequencies of antigen-specific TH2 cells in peripheral blood determined by using HLA class II tetramer analysis most closely paralleled clinical outcomes, IgE antibody-dependent functional assays remained inhibited in part 1 year after discontinuation. CONCLUSION: Two years of allergen immunotherapy were effective but insufficient for long-term tolerance. Allergen-specific TH2 cells most closely paralleled the transient clinical outcome, and it is likely that recurrence of the T-cell drivers of allergic immunity abrogated the potential for durable tolerance. On the other hand, the persistence of IgE blocking antibody 1 year after discontinuation might be an early indicator of a protolerogenic mechanism.
BACKGROUND: Three years of treatment with either sublingual or subcutaneous allergen immunotherapy has been shown to be effective and to induce long-term tolerance. The Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (GRASS) trial demonstrated that 2 years of treatment through either route was effective in suppressing the response to nasal allergen challenge, although it was insufficient for inhibition 1 year after discontinuation. OBJECTIVE: We sought to examine in the GRASS trial the time course of immunologic changes during 2 years of sublingual and subcutaneous immunotherapy and for 1 year after treatment discontinuation. METHODS: We performed multimodal immunomonitoring to assess allergen-specific CD4 T-cell properties in parallel with analysis of local mucosal cytokine responses induced by nasal allergen exposure and humoral immune responses that included IgE-dependent basophil activation and measurement of serum inhibitory activity for allergen-IgE binding to B cells (IgE-facilitated allergen binding). RESULTS: All 3 of these distinct arms of the immune response displayed significant and coordinate alterations during 2 years of allergen desensitization, followed by reversal at 3 years, reflecting a lack of a durable immunologic effect. Although frequencies of antigen-specific TH2 cells in peripheral blood determined by using HLA class II tetramer analysis most closely paralleled clinical outcomes, IgE antibody-dependent functional assays remained inhibited in part 1 year after discontinuation. CONCLUSION: Two years of allergen immunotherapy were effective but insufficient for long-term tolerance. Allergen-specific TH2 cells most closely paralleled the transient clinical outcome, and it is likely that recurrence of the T-cell drivers of allergic immunity abrogated the potential for durable tolerance. On the other hand, the persistence of IgE blocking antibody 1 year after discontinuation might be an early indicator of a protolerogenic mechanism.
Authors: D R Wilson; A M Irani; S M Walker; M R Jacobson; I S Mackay; L B Schwartz; S R Durham Journal: Clin Exp Allergy Date: 2001-11 Impact factor: 5.018
Authors: Marco Frentsch; Olga Arbach; Dennis Kirchhoff; Beate Moewes; Margitta Worm; Martin Rothe; Alexander Scheffold; Andreas Thiel Journal: Nat Med Date: 2005-09-25 Impact factor: 53.440
Authors: Kayhan T Nouri-Aria; Charles Pilette; Mikila R Jacobson; Hiroshi Watanabe; Stephen R Durham Journal: J Allergy Clin Immunol Date: 2005-07 Impact factor: 10.793
Authors: Guy W Scadding; Moises A Calderon; Mohamed H Shamji; Aarif O Eifan; Martin Penagos; Florentina Dumitru; Michelle L Sever; Henry T Bahnson; Kaitie Lawson; Kristina M Harris; Audrey G Plough; Joy Laurienzo Panza; Tielin Qin; Noha Lim; Nadia K Tchao; Alkis Togias; Stephen R Durham Journal: JAMA Date: 2017-02-14 Impact factor: 56.272
Authors: James N Francis; Louisa K James; Giannis Paraskevopoulos; Cheukyee Wong; Moises A Calderon; Stephen R Durham; Stephen J Till Journal: J Allergy Clin Immunol Date: 2008-04-18 Impact factor: 10.793
Authors: Louisa K James; Mohamed H Shamji; Samantha M Walker; Duncan R Wilson; Petra A Wachholz; James N Francis; Mikila R Jacobson; Ian Kimber; Stephen J Till; Stephen R Durham Journal: J Allergy Clin Immunol Date: 2011-02 Impact factor: 10.793
Authors: V Schulten; V Tripple; K Aasbjerg; V Backer; G Lund; P A Würtzen; A Sette; B Peters Journal: Clin Exp Allergy Date: 2016-03 Impact factor: 5.018
Authors: Brian P Vickery; Jelena P Berglund; Caitlin M Burk; Jason P Fine; Edwin H Kim; Jung In Kim; Corinne A Keet; Michael Kulis; Kelly G Orgel; Rishu Guo; Pamela H Steele; Yamini V Virkud; Ping Ye; Benjamin L Wright; Robert A Wood; A Wesley Burks Journal: J Allergy Clin Immunol Date: 2016-08-10 Impact factor: 10.793
Authors: M H Shamji; J H Kappen; M Akdis; E Jensen-Jarolim; E F Knol; J Kleine-Tebbe; B Bohle; A M Chaker; S J Till; R Valenta; L K Poulsen; M A Calderon; P Demoly; O Pfaar; L Jacobsen; S R Durham; C B Schmidt-Weber Journal: Allergy Date: 2017-04-06 Impact factor: 13.146
Authors: Erik Wambre; Jonathan H DeLong; Eddie A James; Nadia Torres-Chinn; Wolfgang Pfützner; Christian Möbs; Stephen R Durham; Stephen J Till; David Robinson; William W Kwok Journal: J Allergy Clin Immunol Date: 2013-12-25 Impact factor: 10.793
Authors: Veronique Bajzik; Hannah A DeBerg; Nahir Garabatos; Blake J Rust; Kimberly K Obrien; Quynh-Anh Nguyen; Colin O'Rourke; Alex Smith; Alex H Walker; Charlie Quinn; Vivian H Gersuk; Mary Farrington; David Jeong; Brian P Vickery; Daniel C Adelman; Erik Wambre Journal: Allergy Date: 2022-03-14 Impact factor: 14.710
Authors: Coleman Murray; Hiromi Miwa; Manjima Dhar; Da Eun Park; Edward Pao; Jessica Martinez; Sireesha Kaanumale; Evelina Loghin; John Graf; Khadir Raddassi; William W Kwok; David Hafler; Chris Puleo; Dino Di Carlo Journal: Lab Chip Date: 2018-08-07 Impact factor: 6.799
Authors: David Larson; Piyush Patel; Anne Marie Salapatek; Peter Couroux; Don Whitehouse; Adela Pina; Jacqueline L Johnson; Michelle L Sever; Srinath Sanda; Julian Poyser; Theresa Allio; Guy W Scadding; Tielin Qin; Mohamed H Shamji; William W Kwok; Eddie A James; Deanna French; Alina Lelic; Mark Larché; Matthew C Altman; Alkis Togias; Stephen R Durham Journal: J Allergy Clin Immunol Date: 2020-03-10 Impact factor: 10.793
Authors: Melinda Y Hardy; Gautam Goel; Amy K Russell; Swee Lin G Chen Yi Mei; Gregor J E Brown; Suyue Wang; Evan Szymczak; Ruan Zhang; Kaela E Goldstein; Kristin M Neff; Leslie J Williams; Kenneth E Truitt; John L Dzuris; Jason A Tye-Din; Robert P Anderson Journal: Front Immunol Date: 2021-05-19 Impact factor: 7.561
Authors: Julia Eckl-Dorna; Sergio Villazala-Merino; Birgit Linhart; Alexander V Karaulov; Yury Zhernov; Musa Khaitov; Verena Niederberger-Leppin; Rudolf Valenta Journal: Front Immunol Date: 2019-01-17 Impact factor: 7.561